Favorable Effects of Burosumab on Fibroblast Growth Factor 23-Related Osteomalacia: A Case Report

Background: Fibroblast growth factor 23 (FGF23) decreases serum phosphate levels by inhibiting proximal tubular phosphate reabsorption and intestinal phosphate absorption by decreasing serum 1,25-dihydroxyvitamin D level, thereby regulating phosphate metabolism. Tumor-induced osteomalacia (TIO) is a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Endocr Soc
Autors principals: Oe, Yuki, Kameda, Hiraku, Nomoto, Hiroshi, Sakamoto, Keita, Soyama, Takeshi, Cho, Kyu Yong, Nakamura, Akinobu, Abo, Daisuke, Kudo, Kohsuke, Atsumi, Tatsuya, Miyoshi, Hideaki
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2021
Matèries:
Bone and Mineral Metabolism
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8090139/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvab048.394
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars